Major Estimate Revision • Jun 02
Consensus revenue estimates fall by 12% The consensus outlook for revenues in fiscal year 2026 has deteriorated. 2026 revenue forecast decreased from AU$105.7m to AU$92.5m. EPS estimate fell from AU$0.031 to AU$0.024 per share. Net income forecast to grow 20% next year vs 13% growth forecast for Medical Equipment industry in Australia. Consensus price target down from AU$0.47 to AU$0.42. Share price fell 27% to AU$0.23 over the past week. Recent Insider Transactions • Mar 12
CEO, MD & Executive Director recently sold AU$138k worth of stock On the 10th of March, Clayton Astles sold around 400k shares on-market at roughly AU$0.34 per share. This transaction amounted to 8.8% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Despite the recent sale, Clayton has been a net buyer over the last 12 months, purchasing a net total of AU$5.8k worth of shares. Reported Earnings • Feb 19
First half 2026 earnings released: EPS: AU$0.013 (vs AU$0.008 in 1H 2025) First half 2026 results: EPS: AU$0.013 (up from AU$0.008 in 1H 2025). Revenue: AU$48.2m (up 31% from 1H 2025). Net income: AU$4.75m (up 62% from 1H 2025). Profit margin: 9.8% (up from 7.9% in 1H 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Medical Equipment industry in Australia. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has increased by 44% per year, which means it is tracking significantly ahead of earnings growth. Recent Insider Transactions • Oct 02
Insider recently sold AU$784k worth of stock On the 30th of September, John Bennetts sold around 2m shares on-market at roughly AU$0.37 per share. This transaction amounted to 3.7% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of AU$716k more than they bought in the last 12 months. Announcement • Sep 29
Austco Healthcare Limited, Annual General Meeting, Oct 29, 2025 Austco Healthcare Limited, Annual General Meeting, Oct 29, 2025. Reported Earnings • Aug 27
Full year 2025 earnings: EPS misses analyst expectations Full year 2025 results: EPS: AU$0.016 (down from AU$0.023 in FY 2024). Revenue: AU$81.4m (up 40% from FY 2024). Net income: AU$5.93m (down 16% from FY 2024). Profit margin: 7.3% (down from 12% in FY 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 20%. Revenue is forecast to grow 18% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Medical Equipment industry in Australia. Over the last 3 years on average, earnings per share has increased by 44% per year whereas the company’s share price has increased by 46% per year. Announcement • Jul 23
Austco Healthcare Limited to Report Fiscal Year 2025 Results on Aug 26, 2025 Austco Healthcare Limited announced that they will report fiscal year 2025 results on Aug 26, 2025 Announcement • May 30
Austco Healthcare Limited (ASX:AHC) completed the acquisition of Guild & Spence Technologies Limited. Austco Healthcare Limited (ASX:AHC) signed a conditional binding term sheet to acquire Guild & Spence Technologies Limited on a cash-free, debt-free basis on April 9, 2025. As part of the consideration, Austco Healthcare Limited shall pay an upfront amount of NZD 7.97 million and rest as earnout payment. The earnout payment will be settled with up to 75% as scrip in Austco Healthcare Limited and remaining in cash. The upfront cash payment shall be subject to adjustments. Austco Healthcare Limited plans to use existing cash reserves to fund the upfront payment.
For the year ending March 31, 2025, Guild & Spence Technologies Limited reported revenue of NZD 22.9 million and EBITDA of NZD 2.9 million.
The deals subject to regulatory consents and approvals, financial and legal due diligence and approval of minority shareholders of Austco Healthcare Limited and Guild & Spence Technologies Limited. The completion is expected to occur on or before June 1, 2025. The transaction is expected to be immediately earnings per share accretive.
Austco Healthcare Limited (ASX:AHC) completed the acquisition of Guild & Spence Technologies Limited on May 30, 2025. Announcement • Apr 09
Austco Healthcare Limited (ASX:AHC) signed a conditional binding term sheet to acquire Guild & Spence Technologies Limited on a cash-free, debt-free basis. Austco Healthcare Limited (ASX:AHC) signed a conditional binding term sheet to acquire Guild & Spence Technologies Limited on a cash-free, debt-free basis on April 9, 2025. As part of the consideration, Austco Healthcare Limited shall pay an upfront amount of NZD 7.97 million and rest as earnout payment. The earnout payment will be settled with up to 75% as scrip in Austco Healthcare Limited and remaining in cash. The upfront cash payment shall be subject to adjustments. Austco Healthcare Limited plans to use existing cash reserves to fund the upfront payment. For the year ending March 31, 2025, Guild & Spence Technologies Limited reported NZD 22.9 million in revenue and NZD 2.9 million in EBITDA. the deals subject to regulatory consents and approvals, financial and legal due diligence and approval of minority shareholders of Austco Healthcare Limited and Guild & Spence Technologies Limited. The completion is expected to occur on or before June 1, 2025. The transaction is expected to be immediately earnings per share accretive. Recent Insider Transactions • Apr 02
CEO, MD & Executive Director recently bought AU$144k worth of stock On the 28th of March, Clayton Astles bought around 500k shares on-market at roughly AU$0.29 per share. This transaction amounted to 14% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Despite this recent buy, Clayton has been a net seller over the last 12 months, reducing personal holdings by AU$35k. Announcement • Dec 16
Austco Healthcare Limited Appoints Ann Larkins as Non-Executive Board Member Austco Healthcare Limited announced the appointment of Ann Larkins as a Non-Executive Board Member, effective immediately. Ann Larkins brings an exceptional combination of clinical expertise and extensive leadership experience in health IT and digital transformation. As the Executive Director and Chief Information Officer (CIO) at the Australian Red Cross Lifeblood, Ann has successfully led significant initiatives, including cloud migrations, infrastructure uplifts and implementing advanced enterprise systems such as SAP SuccessFactors and Oracle FIMS. Before her role at Lifeblood, Ann held senior leadership positions at Barwon Health and Alfred Health, where she led innovative projects as Executive Director and CIO across Health Information Services and ICT Divisions. Her accomplishments include implementing electronic medical records, emergency department and patient administration software, telehealth programs, and patient flow management tools, highlighting her expertise in using technology to improve healthcare efficiency and patient care outcomes. Ann holds a Master of Business Technology from the University of New South Wales, has a Critical Care Nursing clinical background and is a Certified Healthcare CIO (ChiME - College of Healthcare Information Management Executives - USA). This unique combination of clinical and technological expertise has been fundamental to her leadership roles in the healthcare sector. Mrs. Larkins has been appointed by the Board to fill a casual vacany and will stand for re-election at the Company's 2025 Annual General Meeting. Recent Insider Transactions • Oct 24
CEO, MD & Executive Director recently sold AU$103k worth of stock On the 21st of October, Clayton Astles sold around 429k shares on-market at roughly AU$0.24 per share. This transaction amounted to 8.7% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth AU$77m. Clayton has been a net seller over the last 12 months, reducing personal holdings by AU$178k. Announcement • Sep 30
Austco Healthcare Limited, Annual General Meeting, Oct 31, 2024 Austco Healthcare Limited, Annual General Meeting, Oct 31, 2024. Recent Insider Transactions • Sep 21
Insider recently sold AU$77m worth of stock On the 18th of September, Robert Grey sold around 4m shares on-market at roughly AU$19.83 per share. This transaction amounted to 7.4% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of AU$85m more than they bought in the last 12 months. Recent Insider Transactions Derivative • Sep 17
CEO, MD & Executive Director exercised options to buy AU$311k worth of stock. On the 12th of September, Clayton Astles exercised options to buy 1m shares at a strike price of around AU$0.13, costing a total of AU$176k. This transaction amounted to 38% of their direct individual holding at the time of the trade. Since December 2023, Clayton's direct individual holding has increased from 3.63m shares to 4.92m. Company insiders have collectively sold AU$428k more than they bought, via options and on-market transactions in the last 12 months. Reported Earnings • Aug 30
Full year 2024 earnings released: EPS: AU$0.023 (vs AU$0.008 in FY 2023) Full year 2024 results: EPS: AU$0.023 (up from AU$0.008 in FY 2023). Revenue: AU$58.2m (up 39% from FY 2023). Net income: AU$7.08m (up 213% from FY 2023). Profit margin: 12% (up from 5.4% in FY 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has increased by 13% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Jul 12
Austco Healthcare Limited to Report Fiscal Year 2024 Results on Aug 29, 2024 Austco Healthcare Limited announced that they will report fiscal year 2024 results on Aug 29, 2024 Announcement • May 03
Austco Healthcare Limited has completed a Follow-on Equity Offering in the amount of AUD 6.9 million. Austco Healthcare Limited has completed a Follow-on Equity Offering in the amount of AUD 6.9 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 37,297,297
Price\Range: AUD 0.185
Discount Per Security: AUD 0.00925
Transaction Features: Subsequent Direct Listing Recent Insider Transactions Derivative • Jan 09
CEO, MD & Executive Director exercised options and sold AU$102k worth of stock On the 5th of January, Clayton Astles exercised 884.62k options to receive shares at no cost, then sold 794k of them for an average price of -AU$0.13 per share and kept the remainder. For the year to June 2017, Clayton's total compensation was 61% salary and 39% non-salary. Since March 2023, Clayton's direct individual holding has increased from 3.57m shares to 3.63m. Company insiders have collectively bought AU$108k more than they sold, via options and on-market transactions, in the last 12 months. New Risk • Jan 06
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.2% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Shareholders have been diluted in the past year (2.2% increase in shares outstanding). Market cap is less than US$100m (AU$53.3m market cap, or US$35.8m). Announcement • Nov 29
Austco Healthcare Limited (ASX:AHC) completed the acquisition of Teknocorp Australia Pty Ltd. Austco Healthcare Limited (ASX:AHC) entered into a conditional binding term sheet to acquire Teknocorp Australia Pty Ltd for AUD 3.7 million on May 29, 2023. The Purchase Price will be satisfied through an upfront cash payment of AUD 1.9 million and the issue of 3.9 million shares of Austco at issue price based on the 30-day volume weighted average share price of Austco determined two business days before completion along with an earnout amount AUD 1.25 million. Transaction is subject to the Share Consideration being subject to voluntary escrow for the period of the Earnout, entry into executive services agreements of key employees, assignment of key customer and supplier contracts, regulatory consents and approvals, Acquisition is subject to due diligence and austco finalizing its financial and legal due diligence and agreeing on final form transaction documents. The Acquisition is expected to complete early in Q1 of FY24. The Acquisition is expected to be immediately earnings per share accretive, not including any revenue synergy benefits. As on September 25, 2023, Austco Healthcare Limited (ASX:AHC) executed an agreement to acquire Teknocorp Australia Pty Ltd. The acquisition is expected to complete in October 2023. Austco used part of AUD 1 million over-draft facility with a tier one bank debt provider to fund the acquisition.
Austco Healthcare Limited (ASX:AHC) completed the acquisition of Teknocorp Australia Pty Ltd on November 27, 2023. Announcement • Sep 28
Austco Healthcare Limited, Annual General Meeting, Nov 01, 2023 Austco Healthcare Limited, Annual General Meeting, Nov 01, 2023, at 10:00 AUS Eastern Standard Time. Agenda: To consider Adoption of Remuneration Report (non-binding); to consider Re-election of Director Mr Anthony Glenning; to Approval of issue of Performance Rights to Mr Clayton Astles under the Austco Incentive Plan; to Approval of Additional Placement Capacity under ASX Listing Rule 7.1a. Reported Earnings • Aug 25
Full year 2023 earnings released: EPS: AU$0.008 (vs AU$0.008 in FY 2022) Full year 2023 results: EPS: AU$0.008 (in line with FY 2022). Revenue: AU$42.0m (up 17% from FY 2022). Net income: AU$2.26m (down 3.0% from FY 2022). Profit margin: 5.4% (down from 6.5% in FY 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has increased by 26% per year, which means it is well ahead of earnings. New Risk • Aug 24
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Profit margins are more than 30% lower than last year (5.4% net profit margin). Market cap is less than US$100m (AU$55.3m market cap, or US$35.8m). Announcement • May 31
Austco Healthcare Limited (ASX:AHC) entered into a conditional binding term sheet to acquire Teknocorp Australia Pty Ltd for AUD 3.9 million. Austco Healthcare Limited (ASX:AHC) entered into a conditional binding term sheet to acquire Teknocorp Australia Pty Ltd for AUD 3.9 million on May 29, 2023. The Purchase Price will be satisfied through an upfront cash payment of AUD 1.9 million and the issue of AUD 0.7 million of Austco shares at issue price based on the 30-day volume weighted average share price of Austco determined two business days before completion along with an earnout amount AUD 1.25 million. Transaction is subject to the Share Consideration being subject to voluntary escrow for the period of the Earnout, entry into executive services agreements of key employees, assignment of key customer and supplier contracts, regulatory consents and approvals, Acquisition is subject to due diligence and austco finalizing its financial and legal due diligence and agreeing on final form transaction documents. The Acquisition is expected to complete early in Q1 of FY24.The Acquisition is expected to be immediately earnings per share accretive, not including any revenue synergy benefits. Reported Earnings • Feb 22
First half 2023 earnings released: EPS: AU$0.005 (vs AU$0.005 in 1H 2022) First half 2023 results: EPS: AU$0.005 (in line with 1H 2022). Revenue: AU$20.5m (up 29% from 1H 2022). Net income: AU$1.38m (down 8.7% from 1H 2022). Profit margin: 6.7% (down from 9.5% in 1H 2022). Over the last 3 years on average, earnings per share has increased by 2% per year whereas the company’s share price has increased by 4% per year. Board Change • Nov 16
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. Independent Non-Executive Director Tony Glenning was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Announcement • Oct 28
Austco Healthcare Limited, Annual General Meeting, Nov 28, 2022 Austco Healthcare Limited, Annual General Meeting, Nov 28, 2022, at 09:00 AUS Eastern Standard Time. Agenda: To receive and consider, the financial statements of the Company for the financial year ended 30 June 2022, together with the Directors' Report and the Auditor's Report; to consider adoption of remuneration report; to consider directorate reelections; and to consider other matters. Reported Earnings • Aug 26
Full year 2022 earnings released: EPS: AU$0.008 (vs AU$0.012 in FY 2021) Full year 2022 results: EPS: AU$0.008 (down from AU$0.012 in FY 2021). Revenue: AU$35.9m (up 15% from FY 2021). Net income: AU$2.33m (down 32% from FY 2021). Profit margin: 6.5% (down from 11% in FY 2021). Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has only increased by 14% per year, which means it is significantly lagging earnings growth. Announcement • Aug 25
Austco Healthcare Limited Announces Dividend for the Twelve Months Period Ended June 30, 2022, Payable on October 10, 2022 Austco Healthcare Limited announced dividend of AUD 0.00300000 per share for the twelve months period ended June 30, 2022. The dividend payable on October 10, 2022, with a record date of September 19, 2022. Announcement • Jun 03
Austco Healthcare Appoints Andrew Hall as Chief Commercial Officer, Effective 1 July 2022 Austco Healthcare announced that it has strengthened its executive leadership team with the appointment of Andrew Hall to the newly created role of Chief Commercial Officer (CCO) Australia, effective 1 July 2022. Mr. Hall joins Austco Healthcare with more than 17 years of experience in the nurse call and healthcare technology industry and has a proven track record of success in sales leadership, account management, and business development. As CCO, Andy will be responsible for the company's overall business operations in Australia and will work with senior management to develop and implement strategies focused on sustained revenue growth in the hospital and aged-care sectors. Andy will also focus on promoting Austco's market-leading healthcare communications, clinical workflow, and real-time locating (RTLS) solutions. Board Change • Apr 27
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. Independent Non-Executive Director Tony Glenning was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Recent Insider Transactions Derivative • Mar 22
CEO, MD & Executive Director exercised options to buy AU$182k worth of stock. On the 18th of March, Clayton Astles exercised options to buy 1m shares at a strike price of around AU$0.10, costing a total of AU$140k. This transaction amounted to 64% of their direct individual holding at the time of the trade. Since June 2021, Clayton's direct individual holding has decreased from 2.17m shares to 2.08m. Company insiders have collectively bought AU$210k more than they sold, via options and on-market transactions, in the last 12 months. Announcement • Jan 25
Austco Healthcare Limited Provides Earnings Guidance for the Fiscal First Half Year of 2022 Austco Healthcare Limited advised that it expects to report strong revenue from customers for fiscal first half year of 2022, leading to improved Net Profit After Tax (NPAT). Net Profit After Tax to be $1,450,000 to $1,600,000. Better than expected second quarter revenue from customers underpin an estimated 15% increase in for fiscal first half year of 2022 revenue to $16.0 million compared to $13.9 million in the prior comparative period. Further, the company's Open Sales Order book (confirmed orders) remains robust and currently sits at $21.3 million. Whilst the Company continues to successfully manage challenges related to the supply chain crisis, risks still exisit for the business, which will need to be navigated throughout fiscal year 2022. Board Change • Nov 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. Independent Non-Executive Director Tony Glenning was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Board Change • Oct 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. Independent Non-Executive Director Tony Glenning was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Aug 29
Full year 2021 earnings released: EPS AU$0.012 (vs AU$0.01 in FY 2020) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: AU$33.2m (up 5.0% from FY 2020). Net income: AU$3.42m (up 37% from FY 2020). Profit margin: 10% (up from 7.9% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has only increased by 21% per year, which means it is significantly lagging earnings growth. Announcement • May 29
Austco Healthcare Limited Provides Earnings Guidance for the Full Year 2021 Austco Healthcare Limited provided earnings guidance for the full year 2021. For the period, the company advises that it expects its Net Profit After Tax (NPAT) to show an improvement in underlying profitability. Announcement • Dec 20
Austco Healthcare Limited Announces Settlement of Litigation Austco Healthcare Limited announced that a subsidiary company recently instituted legal proceeding in respect to a breach by a party of a non-compete clause. The matter moved quickly to a mediation and the company has received funds in full and final settlement of the claim in the order of $489,000. This will be recognized in the half year accounts to December 31, 2020. Announcement • Dec 16
Austco Healthcare Limited Wins $1.3 Million New Contract Austco Healthcare Limited has received a AUD $1.3 million contract to update the Tacera Nurse Call platform installed at the 700-bed Ng Teng Fong General Hospital (NTFGH) and the 400-bed Jurong Community Hospital (JCH). The strategic partnership between JurongHealth Campus and Austco will ensure that the hospital executes on the vision of improving healthcare for the community through better and cost-effective care. Austco was chosen on the basis that Tacera's software is the only nurse call solution on the market that delivers VoIP Internet Protocol to the patients' bedside and provides a foundation for future products and services. NTFGH and JCH were the first hospitals in Singapore to be designed and built together from the ground up as an integrated healthcare development. They deliver patient-centered services in a seamless and integrated manner for better patient care, greater efficiency and convenience. All beds will feature the Tacera solution and include integrations with JurongHealth's Code Blue Platform, which will deliver the Code Blue rapid response of any hospital in Singapore.
As a further example of JurongHealth's innovative approach to Healthcare, NTFGH and JCH also intend to adopt artificial intelligence technology in the future with the Tacera solution, which will be able to use data to diagnose the patient and improve survival rates. Announcement • Jul 21
Azure Healthcare Limited to Report Fiscal Year 2020 Results on Aug 27, 2020 Azure Healthcare Limited announced that they will report fiscal year 2020 results at 2:59 AM, GMT Standard Time on Aug 27, 2020 
